107 related articles for article (PubMed ID: 1913228)
21. Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer.
Içli F; Günel N; Dinçol D; Karaoğuz H; Demirkazik A
J Surg Oncol; 1992 Aug; 50(4):251-3. PubMed ID: 1640710
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy for advanced urothelial-tract carcinoma.
Sahashi M; Ono Y; Matsuura O; Ohshima S; Fukushima M
Cancer Chemother Pharmacol; 1992; 30 Suppl():S59-62. PubMed ID: 1394820
[TBL] [Abstract][Full Text] [Related]
23. Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group.
J Natl Cancer Inst; 1988 Sep; 80(13):1011-5. PubMed ID: 2900901
[TBL] [Abstract][Full Text] [Related]
24. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung.
Shepherd FA; Evans WK; Burkes R; Paul K; DeBoer G
Am J Clin Oncol; 1986 Oct; 9(5):392-6. PubMed ID: 3776901
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy of advanced gastric carcinoma (stage IV): a randomized study of FAM versus 5-FU plus BCNU.
Villar A; Asensio F; Candel M; Delgado F; Garcia J; Lledó S; Redón J; Roig JV; Sanchez A; Sanchis C
Chemioterapia; 1987 Feb; 6(1):57-62. PubMed ID: 3103932
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
27. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
[TBL] [Abstract][Full Text] [Related]
28. Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Kolarić K; Potrebica V; Stanovnik M
Oncology; 1986; 43(2):73-7. PubMed ID: 3513075
[TBL] [Abstract][Full Text] [Related]
29. An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.
Ohtsu A; Yoshida S; Saito D; Shimada Y; Miyamoto K; Fujii T; Yoshino M; Yoshimori M
Jpn J Clin Oncol; 1991 Apr; 21(2):120-4. PubMed ID: 2067126
[TBL] [Abstract][Full Text] [Related]
30. 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Flechtner H; Queisser W; Heim ME; Henss H; Arnold H; Fritze D; Herrmann R; Fritsch H; Fritz M; Trux FA
Onkologie; 1987 Apr; 10(2):67-71. PubMed ID: 3108738
[TBL] [Abstract][Full Text] [Related]
31. Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.
Yeh KH; Cheng AL; Chen YC; Chen BR; Lee WJ; Lin JT; Lee PH; Chang KJ; Wang CH; Wang TH
J Formos Med Assoc; 1994 Jan; 93(1):20-4. PubMed ID: 7915575
[TBL] [Abstract][Full Text] [Related]
32. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly alternating doxorubicin and cisplatin for advanced gastric carcinoma.
Raida M; Kath R; Arnrich M; Kähler G; Scheele J; Höffken K
J Cancer Res Clin Oncol; 1998; 124(6):335-40. PubMed ID: 9692842
[TBL] [Abstract][Full Text] [Related]
35. Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
Colozza M; Tonato M; Grignani F; Davis S
Cancer; 1988 Jul; 62(2):262-5. PubMed ID: 3383126
[TBL] [Abstract][Full Text] [Related]
36. Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer.
Sohn JH; Jeung HC; Shin HJ; Rha SY; Roh JK; Noh SH; Min JS; Kim BS; Jang WI; Chung HC
Am J Clin Oncol; 2003 Apr; 26(2):203-9. PubMed ID: 12714898
[TBL] [Abstract][Full Text] [Related]
37. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
38. [Adjuvant chemotherapy in gastric cancer. Experience at the National Institute of Nutrition].
León Rodríguez E; Domínguez A
Rev Invest Clin; 1992; 44(2):221-7. PubMed ID: 1439310
[TBL] [Abstract][Full Text] [Related]
39. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
[TBL] [Abstract][Full Text] [Related]
40. Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
Wagener DJ; Hoogenraad WJ; Rougier P; Lusinchi A; Taal BG; Veenhof CH; de Graeff A; Conroy T; Curran D; Sahmoud T; Wils J
Eur J Cancer; 1996 Jul; 32A(8):1310-3. PubMed ID: 8869091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
